# Switching From Oral Dopamine Agonists to Rotigotine

> **NCT01976871** · PHASE4 · COMPLETED · sponsor: **John Winkelman, MD, PhD** · enrollment: 21 (actual)

## Conditions studied

- Restless Legs Syndrome
- Ekbom Syndrome
- Willis-Ekbom Disease

## Interventions

- **DRUG:** Rotigotine

## Key facts

- **NCT ID:** NCT01976871
- **Lead sponsor:** John Winkelman, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-05
- **Final completion:** 2015-12
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01976871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01976871, "Switching From Oral Dopamine Agonists to Rotigotine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01976871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*